Aardvark Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-27.72	-20.59	-7.21	-13.56
Depreciation & Amortization	0.02	0.02	-	0.11
Loss (Gain) From Sale of Investments	-0.06	0.12	1.22	2.32
Stock-Based Compensation	0.61	0.44	0.31	0.41
Provision & Write-off of Bad Debts	0.01	0.12	0.76	0.49
Other Operating Activities	0.32	0.24	-0.83	1
Change in Accounts Payable	1.89	0.8	0.78	0.03
Change in Other Net Operating Assets	-2.36	0.78	-0.86	-1.34
Operating Cash Flow	-27.29	-18.09	-5.82	-10.54
Capital Expenditures	-0.1	-0.11	-	-
Investment in Securities	-124.51	-11.89	-	-
Other Investing Activities	-	-	-	-1
Investing Cash Flow	-124.62	-12	-	-1
Issuance of Common Stock	91.52	0.33	-	0.23
Other Financing Activities	-5.65	-3.34	-	-
Financing Cash Flow	170.87	81.99	-	0.23
Net Cash Flow	18.96	51.91	-5.82	-11.32
Free Cash Flow	-27.39	-18.2	-5.82	-10.54
Free Cash Flow Per Share	-4.34	-4.55	-1.47	-2.71
Levered Free Cash Flow	-	-10.67	-3.54	-
Unlevered Free Cash Flow	-	-10.67	-3.54	-
Change in Net Working Capital	-	-3.22	-0.78	-

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q